A mouse-human chimeric mAb (chLpMab-2 [192] and chLpMab-23 [191]; human IgG1) exhibited high ADCC activity against PDPN-expressing cells and abolished tumor growth in xenograft models. The gene discussed is PDPN; the disease is neoplasm.